Leonard S. Schleifer, President & CEO at REGENERON PHARMACEUTICALS INC (REGN), sold 218,389 shares at $300.33 ($66.3M) on 2013-09-19, disclosed to the SEC on 2013-09-20.
Scheduled sale ($66.3M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $304.38 | 6,808 | $2.1M | 3.1% |
| 2 | $304.38 | 108,632 | $33.1M | 49.9% |
| 3 | $300.33 | 36,334 | $10.9M | 16.5% |
| 4 | $301.45 | 15,611 | $4.7M | 7.1% |
| 5 | $302.68 | 15,625 | $4.7M | 7.1% |
| 6 | $303.38 | 5,103 |
| $1.5M |
| 2.3% |
| 7 | $304.36 | 10,645 | $3.2M | 4.9% |
| 8 | $305.50 | 7,026 | $2.1M | 3.2% |
| 9 | $306.47 | 7,248 | $2.2M | 3.4% |
| 10 | $307.20 | 1,157 | $355K | 0.5% |
| 11 | $308.70 | 1,200 | $370K | 0.6% |
| 12 | $309.80 | 1,200 | $372K | 0.6% |
| 13 | $310.14 | 1,800 | $558K | 0.8% |
| Total | $303.57 avg | 218,389 | $66.3M | 100% |
| Filing → |
| REGN | SELL | 2024-05-17 | $44.7M | — | Filing → |
| REGN | SELL | 2024-05-15 | $70.1M | — | Filing → |
| REGN | SELL | 2022-04-07 | $10.1M | — | Filing → |